Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.

Abstract

INTRODUCTION:

Measurement of tumor response by standard response criteria is challenging in thymic malignancies, especially when the pleura is involved, as it often is in stage IV disease. In this study, we aimed to determine the effectiveness of volumetric response evaluation criteria in solid tumors (volumetrics) for evaluating response in patients with thymic malignancies treated on a phase II study of belinostat.

METHODS:

We evaluated the tumor responses of 25 patients with thymic cancer using computed tomography-based RECIST, World Health Organization (WHO), modified RECIST, and volumetrics. As a control, we assessed 37 patients with non-small cell lung cancer (NSCLC) with RECIST and volumetrics.

RESULTS:

Agreement analyses in 23 patients with thymic cancer at the time of RECIST-determined progressive disease (PD) compared volumetrics with RECIST, modified RECIST, and WHO criteria. Use of volumetrics was associated with 22% discordance compared with RECIST, 15% versus modified RECIST, and 22% versus WHO criteria. Volumetrics revealed PD 72 days earlier than RECIST (p = 0.016). In another cohort of 35 patients with NSCLC, there was 9% discordance between volumetrics and RECIST at the time of PD. Volumetrics demonstrated PD 32 days earlier than RECIST in NSCLC (p = 0.0078).

CONCLUSIONS:

Our study suggests that volumetrics might improve detection of PD. Prospective evaluation of this technique in a larger series of patients with thymic malignancies will be required.

• Authors: Jeremy Force, Arun Rajan, Eva Dombi, Seth M Steinberg, Giuseppe Giaccone
• Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 6 Issue 7 Pg. 1267-73 (Jul 2011) ISSN: 1556-1380 [Electronic] United States
• PMID: 21610525 (Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Benzenesulfonates
• Hydroxamic Acids
• Phenylurea Compounds
• Pyridines
• Sulfonamides
• Niacinamide
• Sorafenib
• belinostat

Topics

• Adenocarcinoma (diagnostic imaging, drug therapy, secondary)
• Adolescent
• Adult
• Aged
• Antineoplastic Agents (therapeutic use)
• Benzenesulfonates (therapeutic use)
• Carcinoma, Large Cell (diagnostic imaging, drug therapy, secondary)
• Carcinoma, Non-Small-Cell Lung (diagnostic imaging, drug therapy, secondary)
• Carcinoma, Squamous Cell (diagnostic imaging, drug therapy, secondary)
• Female
• Follow-Up Studies
• Humans
• Hydroxamic Acids (therapeutic use)
• Lung Neoplasms (diagnostic imaging, drug therapy, pathology)
• Male
• Middle Aged
• Neoplasm Staging
• Niacinamide (analogs & derivatives)
• Phenylurea Compounds
• Prospective Studies
• Pyridines (therapeutic use)
• Retrospective Studies
• Sorafenib
• Sulfonamides
• Survival Rate
• Thymoma (diagnostic imaging, drug therapy, pathology)
• Thymus Neoplasms (diagnostic imaging, drug therapy, pathology)
• Tomography, X-Ray Computed
• Treatment Outcome
• Young Adult